Table 1.
Randomized controlled trials of anticoagulant therapy for cancer-associated venous thromboembolism
|
Study (Ref. #) |
Duration | Tested LMWH | Recurrent VTE | Major bleeding | ||
| LMWH | VKA | LMWH | VKA | |||
|
CLOT (8) |
6 months | Dalteparin | 27/336 (8%) | 53/336 (15.8%)* | 19/338 (5.6%) | 12/335 (3.6%) |
|
CATCH (9) |
6 months | Tinzaparin | 31/449 (6.9%) | 45/451 (10%) | 12/449 (2.7%) | 11/451 (2.4%) |
|
CANTHANOX (10) |
3 months | Enoxaparin | 2/71 (2.8%) |
3/75 (4%) |
5/71 (7%) |
12/75 (16%) |
|
ONCENOX (11) |
6 months | Enoxaparin | 4/61 (6.6%) |
3/30 (10%) |
6/67 (8.9%) | 1/34 (2.9%) |
|
LITE (12) |
3 months | Tinzaparin | 18/369 (4.9%) | 21/368 (5.7%) | 10/144 (6.9%) |
13/146 (8.9%) |
|
Study (Ref. #) |
Duration | Tested DOAC | Recurrent VTE | Major bleeding | ||
| DOAC | dalteparin | DOAC | dalteparin | |||
|
SELECT-D (29) |
6 months | Rivaroxaban | 8/203 (3.9%) | 18/203 (8.9%)* | 11/203 (5.4%) |
6/203 (3%) |
|
Hokusai VTE Cancer (30) |
Up to 9 months | Edoxaban | 41/522 (7.9%) | 59/524 (11.3%) | 36/522 (6.9%) | 21/524 (4%)* |
|
ADAM VTE (31) |
6 months | Apixaban |
0/145 (0%) |
2/142 (1.4%) | 1/145 (0.7%) | 9/142 (6.3%) |
|
Caravaggio (32) |
6 months | Apixaban | 32/576 (5.6%) | 46/579 (7.9%) | 22/576 (3.8%) | 23/579 (4%) |
The upper part of the table shows the frequency of recurrent venous thromboembolism (VTE) and major bleeding in randomized controlled trials comparing different types of low-molecular-weight heparin (LMWH) with vitamin K antagonists (VKA), while the lower part presents the same outcomes in trials evaluating direct oral anticoagulants (DOAC) vs. dalteparin. Event rates are expressed as total number divided by treated patients, as published
*Indicates significant difference for the corresponding hazard ratio